BioMarin Pharmaceutical (NASDAQ:BMRN)

bigger fish

3 Biotech Stocks Could Be the Next Big Takeover Targets

Just as the biotech segment was starting to regain lost ground, and was fast approaching 2016 highs, yet another speed bump was hit. The EpiPen controversy, and the resulting commentary again ...
Read Full Story »
money

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

The Nasdaq Biotechnology Index has underperformed the broader market for some time. This year the index is still down about 13%, versus the 6% rise for the S&P 500. We ...
Read Full Story »
Test tubes

JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now

We have noted recently that large pharmaceuticals and biotech have been hammered, and now may be offering outstanding total return potential. While the larger pharmaceutical stocks have done better recently, the ...
Read Full Story »
FDA_logo

4 Major FDA Decisions Expected by June

Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount ...
Read Full Story »
biotech word cloud

Analysts Make Major Changes to Top Biotech Ratings

At different times of the year, certain sectors come alive or slow down. Typically each year, the first quarter is the slowest for the biotechs, so many analysts tend to ...
Read Full Story »
Test tubes

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

All sectors of the market tend to have times of the year that are better than others, and biotechnology is no different. Typically each year, the first quarter is the ...
Read Full Story »
hospital entrance

Can BioMarin Make Treating Hemophilia More Affordable?

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is ready to break above the $1 billion revenue barrier in 2016. This is a feat that marks a major hurdle for many biotech and emerging ...
Read Full Story »
automatic inspection machine

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

Biotech stocks have been absolutely beaten up over the past eight months, even the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) is down over 20% year to date. However this could ...
Read Full Story »
Female patient on gurney

BioMarin Sinks Despite Meeting Primary Endpoint

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) made waves early Monday following the release of late-stage results from its pegvaliase study. The company announced that the pivotal Phase 3 PRISM-2 study of pegvaliase ...
Read Full Story »
Starbucks coffee

4 Top Jefferies Growth Stocks to Buy With Big Upside Potential

After the massive rally on Friday, it will be interesting to see how the markets trade this week. Some anecdotal Wall Street data indicate that money managers and traders are still ...
Read Full Story »
FDA_logo

5 Key FDA Decisions Expected in March

Companies in the pharmaceutical industry are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, ...
Read Full Story »
biotech word cloud

Top Biotech Stocks Dominate Jefferies Growth Stocks to Buy This Week

One group that was absolutely buried during the sell-off was the biotechs. In fact, since the highs printed in July of last summer, the IBB index that tracks the industry is still down ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Huntington Bancshares, Nucor, Orexigen, SanDisk, Square, VIVUS and Many More

Stocks were indicated to open lower on Monday morning, but that is after two weeks of a rally. Is it possible that the trend of selling into every rally is ...
Read Full Story »
Pills and tablets

How Analysts Changed Views on BioMarin After Earnings

BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN) reported its fourth-quarter financial results after the markets closed Thursday. Investors really took to this stock and there was a favorable jump after the report. ...
Read Full Story »
biotech word cloud

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. There is a challenging macro setup, but headwinds combined with a relatively attractive valuation could carry ...
Read Full Story »